Evidence map›Paper›PMID 41095904›Full record

ArticleJournal of clinical medicine2025

KRAS G12C Mutation Predicts Improved Survival in NSCLC Patients Receiving Immunotherapy: Insights from a Real-World Cohort.

Aslı Geçgel, Buket Şahin Çelik, Pınar Peker, Zeynep Sıla Gökdere, Didem Koca, Burçak Karaca, Deniz Nart, Erdem Göker

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Targeting KRASFrontiers in oncology · 2026
    Pooled it
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Aslı GeçgelDepartment of Medical Oncology, Faculty of Medicine, Ege University, Kazım Dirik District, 35100 Izmir, Turkey.ORCID 0000-0001-6942-9858
Buket Şahin ÇelikDepartment of Medical Oncology, Bursa Ali Osman Sönmez Oncology Hospital, 16040 Bursa, Turkey.
Pınar PekerDepartment of Medical Oncology, Adana City Hospital, 01370 Adana, Turkey.
Zeynep Sıla GökdereDepartment of Medical Oncology, Faculty of Medicine, Ege University, Kazım Dirik District, 35100 Izmir, Turkey.
Didem KocaDepartment of İnternal Medicine, Faculty of Medicine, Ege University, 35100 Izmir, Turkey.
Burçak KaracaDepartment of Medical Oncology, Faculty of Medicine, Ege University, Kazım Dirik District, 35100 Izmir, Turkey.
Deniz NartDepartment of Medical Pathology, Faculty of Medicine, Ege University, 35100 Izmir, Turkey.
Erdem GökerDepartment of Medical Oncology, Faculty of Medicine, Ege University, Kazım Dirik District, 35100 Izmir, Turkey.ORCID 0000-0001-6180-713X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

immune checkpoint inhibitorKRAS G12C mutationnon-small cell lung canceroverall survival

Identifiers

PMID41095904
PMCPMC12525381

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.